The global market for Endoscopic Retrograde Cholangiopancreatography (ERCP) devices is poised for robust growth, with sales projected to climb from USD 1,628.6 million in 2024 to USD 3,000.2 million by 2034. This growth represents a compound annual growth rate (CAGR) of 6.3% over the forecast period, signaling a transformative decade for gastrointestinal and pancreatic biliary …